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ABSTRACT
The Escherichia coli McrA protein, a putative
C
5-methylcytosine/C
5-hydroxyl methylcytosine-
specific nuclease, binds DNA with symmetrically
methylated HpaII sequences (Cm5CGG), but its
precise recognition sequence remains undefined.
To determine McrA’s binding specificity, we cloned
and expressed recombinant McrA with a C-terminal
StrepII tag (rMcrA-S) to facilitate protein purification
and affinity capture of human DNA fragments with
m5C residues. Sequence analysis of a subset of
these fragments and electrophoretic mobility shift
assays with model methylated and unmethylated
oligonucleotides suggest that N(Y`R) m5CGR is
the canonical binding site for rMcrA-S. In addition
to binding HpaII-methylated double-stranded DNA,
rMcrA-S binds DNA containing a single, hemi-
methylated HpaII site; however, it does not bind if
A, C, T or U is placed across from the m5C residue,
but does if I is opposite the m5C. These results
provide the first systematic analysis of McrA’s
in vitro binding specificity.
INTRODUCTION
Wild-type Escherichia coli K-12 strains possess several
restriction systems in addition to the classical EcoK
hsdR/M/S host-speciﬁcity restriction-modiﬁcation mecha-
nism. One of these, for methylated adenine recognition
and restriction (Mrr) has been reported to restrict DNA
containing N
6-methyladenine and also DNA with
C
5-methylcytosine residues (m5C) (1–4). Neither system
restricts DNA methylated by the resident E. coli
enzymes encoded by dam, which methylates the A
residue in the sequence GATC, or by dcm, which
modiﬁes the internal cytosine in CCWGG (W is A or T)
sequences at the C
5 position (1,3,5).
DNA containing C
5-methylcytosine (m5C) or
5-hydroxymethyl cytosine (Hm5C) is also restricted by
the modiﬁed cytosine restriction (Mcr) system which is
identical to the previously described restricts glucose-less
phage (Rgl) restriction system that blocks the growth of
T-even phages, but only when they contain Hm5C, i.e.
when their Hm5C DNA residues are not glucosylated
(6–8). Later work further subdivided the Mcr system
into two genetically distinct regions: McrA (equal to
RglA) on an easily excisable but defective lambdoid
prophage element e14 located at 25min on the E. coli
K-12 chromosome (8–9) and McrB (or RglB) at map
position 99minina region that includes the EcoK
restriction/modiﬁcation and Mrr systems (2,4,8,10).
McrA recognizes DNA containing C
5-methylcytosine or
C
5-hydroxymethylcytosine while McrB also recognizes
DNA containing N
4-methylcytosine. The mcrB locus
encodes two polypeptides McrB and C which together
function as a nuclease recognizing in cis two half sites
50-G/A 5mC (N40–3000) G/A 5mC-30. Cleavage requires
GTP hydrolysis and occurs at a non-ﬁxed distance ( 30
nucleotides) between the two methylated half sites (11,12).
Early studies showed that DNAs methylated by
M.HpaII (Cm5CGG), M.Eco1831I (Cm5CSGG where
S is C or G) and M.SssI (m5CG) are restricted by the
McrA system (2,5,13) and further studies demonstrated
that clones expressing the McrA open reading frame
conferred both McrA and RglA phenotypes on mcr
minus E. coli strains (8). Several indirect studies suggest
that McrA is a member of the ßßa-Me ﬁnger superfamily
of nucleases. Its ßßa-Me ﬁnger also contains an HNH
motif common to homing endonucleases as well as many
restriction and DNA repair enzymes. The core ßßa-Me
domain of McrA (residues 159–272 of the 277 amino
acid long polypeptide) was modeled by Bujnicki and cow-
orkers using a protein sequence threading approach (14).
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and 256) predicted to coordinate a Mg
2+ ion, as well as
four cysteine residues (C-207, 210, 248 and 251) which
are thought to form a zinc ﬁnger, most likely involved in
coordinating Zn
2+ or some other divalent metal ion to
help stabilize the protein’s structure and/or help catalyze
nuclease activity.
While McrA is predicted to function as a nuclease and
induces the DNA damage response (an index of cleavage
activity) when a suitable substrate is present (15),
McrA-mediated nuclease activity in vitro has never been
demonstrated and to date the mechanism for McrA’s
biological restriction of modiﬁed phage or plasmid DNAs
is not known. Recently we reported on the cloning, expres-
sion, puriﬁcation and initial characterization of full-
length, biologically active rMcrA (16). However, while
all attempts to demonstrate that rMcrA is a nuclease
acting on m5C-containing DNA were unsuccessful,
electrophoretic mobility shift analysis demonstrates
that puriﬁed rMcrA interacts speciﬁcally with DNA frag-
ments containing Cm5CGG sequences. This prompted us
to design experiments to determine the spectrum of
endogenously methylated McrA targets in human DNA.
In order to address this question we successfully employed
McrA fused to an eight-amino-acid long StrepII tag
(rMcrA-S) to aﬃnity-capture methylated restriction frag-
ments from total human DNA. Standard sequencing of
these fragments, together with bisulﬁte genome-sequencing
analysis of their original loci in human DNA revealed
more fully the DNA-binding proﬁle of McrA. We also
used rMcrA-S in electrophoretic mobility shift assays
(EMSAs) with symmetrically methylated,hemimethylated-
andnon-methylated-double-stranded DNA probes with a
canonical HpaII site and various single base-pair permu-
tations ﬂanking the central m5CpG dinucleotide or
opposite the m5C residue. Together, these data help
deﬁne the minimal recognition sequence and base-pairing
requirements for McrA’s interaction with DNA.
MATERIALS AND METHODS
Oligonucleotides
Oligonucleotides were purchased from Integrated DNA
Technologies. We dissolved individual oligonucleotides
with and without m5C in 10mM Tris–HCl, 0.01mM
EDTA buﬀer, pH 7.5, and, as needed, annealed them
at 36mM with their complements, in 1 One-Phor-All
Buﬀer (10mM Tris–Acetate pH 7.5, 10mMMg–Acetate,
50mMK–Acetate) (GE Healthcare) by heating for 2min
at 98 C, then slow cooling to room temperature. With
10% PAGE analysis, we veriﬁed their conversion to
duplexes, leaving only minimal amounts (<5%) of
residual single-stranded oligonucleotides. Supplementary
Tables S2a and b list the oligonucleotides used for this
study and give the sequences of their resulting fully
base-paired ds-cassettes. Supplementary Table S3 shows
the oligonucleotide cassettes used to determine the
binding of rMcrA-S to ds-cassettes with a mismatched
base opposite m5C. Oligonucleotides 1–6 were synthesized
with m5C at various positions, while the remaining ones
were methylated post-synthesis, when needed, using the
ds-speciﬁc CpG methylase (M.SssI) after annealing to
form duplexes, as described above. A typical reaction
(20ml) included 180pMol duplex DNA in 1 SssI
buﬀer (10mM Tris–HCl, 50mM NaCl, 10mM MgCl2
and 1mM dithiothreitol) supplemented with 160mM
S-adenosylmethionine (SAM). Reactions were started by
adding eight units of M.SssI enzyme and incubating the
mix overnight at 37 C, then spiking with additional SAM
for a ﬁnal concentration of 320mM, and ﬁnally incubating
the samples at 37 C for another 2h. The M.SssI
was inactivated by heating at 65 C for 20min. To check
that methylation was complete, we included as a control a
duplex containing a single HpaII (CCGG) site, and no
other CpG dinucleotides. We then checked that the
DNA was protected against digestion by HpaII (methyl
sensitive), but was susceptible to digestion by the
methyl-insensitive isoschizomer MspI. For each assay,
2ml of methylation reaction was added to 10mM Bis–
Tris–Propane–HCl, 10mM MgCl2, 1mM dithiothreitol
supplemented with 100mg/ml BSA, followed by 10 units
of either HpaII or MspI enzyme. Reactions were incubated
at 37 C for 2h before being analyzed by agarose-gel
electrophoresis. Gels were stained with ethidium bromide
and the DNA bands visualized under UV light.
Strains and enzymes
Escherichia coli Top10 (Invitrogen) was used for DNA
manipulation and plasmid preparations. Strain BL21-AI
was obtained from Invitrogen. All enzymes, unless other-
wise stated, were purchased from New England Biolabs.
rMcrA-S
The recombinant McrA coding sequences used here with
either an eight amino-acid N terminal or a C terminal
StrepII tag (17) (underlined) (MASWSHPQFEKGA-
start of McrA or end of McrA–SAWSHPQFEK, respec-
tively) were constructed by PCR ampliﬁcation from a wild-
type, untagged mcrA clone. We used primers that
appended the StrepII tag and unique restriction sites to
aid in cloning on the ends of the PCR product. After
restriction-enzyme digestion and gel-puriﬁcation, the
amplicons were cloned into pET28. Details and clones
are available on request. We veriﬁed the accuracy of the
clones by DNA sequencing and then moved them into the
expression host BL21(DE3)/pRIL; the recombinant
proteins were expressed following autoinduction at 20 C
as previously described (16). The departure here was that
after SP-Sepharose Fast Flow (Pharmacia Biotech) chro-
matography, we further puriﬁed the recombinant proteins
by binding them to Strep Tactin SpinPrep
TM ﬁlters
(Novagen), followed by elution with LEW buﬀer (50mM
NaPO4, pH 8.0; 300mM NaCl) containing 10mM biotin.
The puriﬁed proteins were stored at 4 C. Preliminary
studies (data not shown) indicated that the N-terminal
tagged protein (rS-McrA) was markedly less eﬃcient in
binding HpaII-methylated DNA fragments to
streptavidin-coated magnetic beads (Nanolink) than was
its C-terminal analogue (rMcrA-S); therefore, the latter
was utilized in all remaining experiments.
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Human genomic A549 DNA (lung carcinoma) was
digested exhaustively with MseI whose recognition sites
(TTAA) rarely occur in GC-rich regions, so that most
regions with a high density of m5CpG dinucleotides
were left intact. The digested DNA was phenol-extracted,
precipitated with ethanol, and then dissolved in
10mM Tris–HCl, 0.01mM EDTA (TEsl), pH 8.0.
Approximately 750ng of fragmented DNA was incubated
for 20min at RT with  7nmol of rMcrA-S in 200ml
LEW buﬀer supplemented with 100mg/ml BSA and
250ng sonicated E. coli ER2925 (dam
 , dcm
 ) DNA as
the carrier. Then we added a 25ml bed-volume of
Nanolink magnetic strepavidin beads, prewashed twice
in 1 LEW+100mg/ml BSA, and incubated the mate-
rials at RT for 1h with gentle mixing to capture the
rMcrA-S/A549 DNA complexes. The unbound fraction
was removed and the beads were washed 3 with 100ml
1 HEPES+250mM NaCl; 3 with 1 HEPES+
700mM NaCl; and, 2  with 50ml1  HEPES+
250mM NaCl. The beads with the bound DNA fragments
next were washed in 50ml1 Quick Ligase Buﬀer (NEB)
[66mM Tris–HCl, 10mM MgCl2, 1mM dithiothreitol,
1mM ATP and 7.5% (W/V) polyethylene glycol (PEG
6000)] and resuspended in 50ml1  Quick Ligase Buﬀer.
Ligation-mediated PCR (LM-PCR)
A MseI-compatible adaptor DNA cassette was formed by
annealing two oligonucleotides: MseI Top: 50-AGCAACT
GTGCTATCCGAGGGAT-30, and MseI Bottom: 50-TA
ATCCCTCGGA-30 and then ligating the product to the
MseI-compatible ends of the DNA captured on the
strepavidin beads by rMcrA-S. We added 100pmol of
adaptor and 3000 U of T4 DNA ligase to the resuspended
magnetic beads in 50ml1  Quick Ligation Buﬀer. The
reaction was incubated at 16 C overnight.
The beads were then washed and equilibrated with
100ml1  Thermo Pol Buﬀer (NEB) (20mM Tris–HCl
pH 8.8, 10mM KCl, 10mM (NH4)2SO4, 2mM MgSO4,
0.1% Triton X-100). PCR ampliﬁcation was done in 50ml
NEB Thermo Pol buﬀer with Taq polymerase using a
single unphosphorylated primer: 50-AGCAACTGTGCT
ATCCGAGGGAT-30. The reactions were started by
incubating the material at 72 C for 10min to ﬁll-in the
single-stranded regions of the appended cassettes, and
then were cycled 14 times at 94 C for 20s, 68 C for 30s
and 72 C for 2min 30s. The ampliﬁed products were
puriﬁed using Qiagen PCR Puriﬁcation Kit columns
(Qiagen), and resuspended in 20ml of distilled H2O with
50mM HEPES (pH 7.5). Linkered fragments were cloned
using a pSMART GC kit (Lucigen). Individual
recombinant clones were sequenced using standard ABI
dideoxy sequencing.
Bisulﬁte sequencing
Genomic A459 DNA was bisulﬁte-converted according to
the manufacturer’s instructions (Qiagen), followed by
whole-genome ampliﬁcation (Qiagen); we omitted the
initial denaturing steps since the DNA already was
single-stranded after bisulﬁte conversion. Primers were
designed (http://www.urogene.org/methprimer/index1
.html) for two regions of the bisulﬁte-modiﬁed genomic
DNA. Region C1 was ampliﬁed using the forward- and
reverse-primers, C1F3: 50-TGGGGTGTTTTTTTTGTA
TT-30 and C1R1: 50-AAAATCCCACCCTAAACC-30,
respectively, and region C2 with the forward and reverse
primers C2F3: 50-TGGGTTTTGTATAGGTTAAA-30
and C2R1: 50-AACAACCAAAAAATTTTCAC-30,
respectively. PCR was done following the manufacturer’s
conditions, using NEB Thermo Pol buﬀer and Taq
polymerase supplemented with 5% DMSO (ﬁnal concen-
tration) and ampliﬁed as follows: 94 C for 2min, two
cycles of (94 C for 30s, 55 C for 30s, 72 C for 2min)
2 cycles of (94 C for 20s, 54 C3 0s ,7 2  C for 2min) two
cycles of (94 C for 20s, 53 C for 30s, 72 C for 2min) two
cycles of (94 C for 20s, 52 C for 30s, 72 C for 2min) and
30 cycles of (94 C for 20s, 51 C for 30s, 72 C for 2min).
PCR products were gel puriﬁed using PCR puriﬁca-
tion columns (Qiagen), ligated into pCR4TOPO vector
(Invitrogen) via manufacturer’s standard protocol,
electroporated into E. coli Top 10 cells, and plated on
2 YT supplemented with 50mg kanamycin. We picked
individual colonies and grew them in 2 YT media with
50mg kanamycin. Plasmids were isolated using alkaline
lysis followed by column puriﬁcation (Fermentas), and
sequenced with primers ﬂanking the cloning site.
Sequencher software (Gene Codes) was employed to edit
the sequences, and CLUSTLW to analyze them.
EMSA binding assays
Reactions (10ml) typically contained a mixture of
10–25pMol of various test DNAs, and 250ng sonicated
E. coli ER2925 DNA as a non-methylated, non-speciﬁc
competitor in 50mM Tris–HCl, 100mM NaCl, 1mM
dithiothreitol, 10mM MgCl2 (NEBuﬀer No.3), supple-
mented with 100mg/ml BSA. We started the reactions
adding 25–175pMol McrA-S; after 45min at RT, the
entire sample was loaded on 10% acrylamide Tris–
Acetate/EDTA gel (1 TAE: 40mM Tris–acetate, 1mM
disodium EDTA) which was electrophoresed at RT.
Thereafter, the gels were stained with ethidium bromide
(0.5mg/ml) at RT and visualized with UV light. Then, we
stained the gels with Coomassie Blue to detect rMcrA-S.
RESULTS
Previously, we reported that puriﬁed full-length
recombinant McrA (rMcrA) binds to but lacks detectable
nuclease activity at methylated HpaII (Cm5CGG)
sequences (16) and, as such, might aﬀord utility as a
reagent for aﬃnity puriﬁcation of human DNA fragments
containing m5C and possibly Hm5C residues (18,19). The
human genome contains  2.3-million HpaII sites of which
roughly 12% are located in regions with a high density of
m5CpG dinucleotides, regions referred to as CpG islands
(CGIs) (Supplementary Table S1). The human genome
has  30000 CGIs, accounting for  10% of the total
DNA, about half of which are located near annotated
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intra- or intergenic (non-TSS). In normal tissues,
TSS-CGIs usually are unmethylated but a subset
becomes reproducibly methylated in normal cells during
imprinting, X-chromosome inactivation, tissue diﬀerenti-
ation and in diseased and cancerous cells (20–22).
Consequently, there is growing interest in determining
global DNA methylation patterns in normal- and
abnormal-tissues. Widely used methods for such studies
include immunoprecipitation (23); methylation speciﬁc
PCR (24); m5CpG aﬃnity-capture using m5CpG-
binding proteins and related methods (25,26) restriction
enzyme-based methods, microarray-based methods or
various combinations of these methods (27–29) and
bisulﬁte-based modiﬁcation followed by single or multi-
locus DNA sequencing or more recently by high-
throughput, massively parallel sequencing (27).
Since our initial McrA studies used phage T7 DNA
methylated in vitro only at HpaII sites, we could not ascer-
tain whether McrA also can bind to, and perhaps be used
for aﬃnity puriﬁcation of DNA fragments with related
sequences containing m5CpG’s or, alternatively, if McrA
would preferentially enrich a subset of eukaryotic CGIs
containing several methylated HpaII sites. A standard
technique for converting McrA into such an aﬃnity
reagent would be to fuse a (His)6 tag to either end of the
protein and then use the tagged protein to generate an
aﬃnity matrix for binding DNA fragments containing
m5CpG’s. However, rMcrA intrinsically binds to
Ni-charged NTA supports, presumably because of inter-
action with three suitably positioned histidines in its
ßßa-Me domain (14,16). Our initial experiments indicated
ineﬃcient binding of rMcrA/DNA complexes to
Ni-charged NTA magnetic beads, presumably due to
steric hindrance. Therefore, we decided to add an eight-
amino-acid long StrepII tag (WSHPQFEK) (17) to one
end of the protein to foster the aﬃnity capture of
methylated DNA fragments independent of the
Ni-binding site. In our hands, placing this tag at the
C-terminus does not seem to adversely aﬀect the protein’s
capture of DNA fragments with methylated-HpaII
sequences, whereas its N-terminal tagged counterpart is
much less eﬀective (data not shown).
To further resolve McrA’s binding speciﬁcity, we ini-
tially used rMcrA-S to enrich for methylated sequences
from an MseI digest of genomic human DNA because it
would contain m5CpG dinucleotides in all possible
contexts, and further, MseI leaves CGIs mostly intact
(25). In addition, this way we could ascertain whether
rMcrA-S preferentially captures CGIs with methylated
HpaII sites. Accordingly, we washed bound fragments
obtained by rMcrA-S aﬃnity puriﬁcation with high-
ionic-strength buﬀer, and then LM-PCR-ampliﬁed,
cloned, and sequenced a subset of the clones to determine
if they all contained HpaII sites, and if any originated
from chromosome regions deﬁned as being a CGI. We
found that most clones from a library of non-size-selected
amplicons were not from CGIs, but from regions contain-
ing repetitive sequences; i.e. regions known to contain
m5CpGs. Some minor enrichment for CGI fragments
was noted when the ampliﬁed DNA was gel-puriﬁed and
fragments between 0.5- and 2-kb were used to prepare the
library (viz. the size range expected for CGIs in the digest).
While many clones in both libraries contained one or more
HpaII sites, some had no HpaII sites although they
invariably contained several CpG dinucleotides. Overall,
we found  2–3-fold increase in CpG dinucleotides in these
libraries over the starting DNA (Figure 1).
After we located all aﬃnity captured sequences in the
human genome using the UCSC Genome Browser
(March, 2006 assembly, http://genome.ucsc.edu/), we
chose two unique regions to study further: ‘C1’, within
Ch. 8q24.3, containing two HpaII sites, one CGG
sequence and ﬁve other CpG dinucleotides; and, ‘C2’,
within Ch. 18q11.2, lacking HpaII sites but having a
single CGG sequence plus three other CpGs within the
MseI fragment. We next determined the methylation
status of these sites in vivo via sodium-bisulﬁte sequencing.
Brieﬂy, total genomic A549 DNA was bisulﬁte-modiﬁed,
ampliﬁed by a whole-genome ampliﬁcation assay, and
then the C1 and C2 regions were ampliﬁed using
bisulﬁte-speciﬁc primers C1F3, C1R1 and C2F3, C2R1,
respectively. Standard sequencing methods allowed us to
deduce the genomic methylation pattern in 12 clones from
each region.
Aligning these sequences showed that 63–100% of all
CpG sites in C1 were methylated, and all C1 clones had at
least one methylated HpaII sequence or m5CGG sequence
(hereafter referred to as a three–fourth HpaII site) (Figure
2a). For the C2 clones, from a region lacking HpaII sites,
we found that all 12 clones were methylated at the three–
fourth HpaII site (Figure 2b). Ten of them exhibited 100%
methylation across all four CpG dinucleotides. These data
led us to investigate whether the three–fourth HpaII site is
a minimal binding site for rMcrA-S.
To further deﬁne a consensus rMcrA-S DNA recogni-
tion site, we turned to EMSA using 24bp synthetic
oligonucleotide cassettes containing one of the following:
Figure 1. CpG ratios in the human genome versus rMcrA-s
pull-downs. Dinucleotide frequencies compiled for both strands of 33
unique rMcrA-S pull-down fragments (11400-nt total), compared with
total-genome frequencies compiled from UCSC hg18. (http://genome
.ucsc.edu/cgi-bin/hgTracks?hgsid= 136554479&chromInfoPage=).
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(Cm5CGG); (ii) one with a single m5C in a ‘three–
fourth HpaII site’ (m5CGG); and (iii) one containing a
single m5C in an HpaII site. As a control, we used a
ds-cassette with no m5Cs (Supplementary Table S2b).
Figure 3 shows that, at the protein/DNA ratios we used,
rMcrA-S has high aﬃnity for a ds-cassette containing a
single symmetrically methylated HpaII site; however, at
higher ratios of protein to DNA, binding to the cassette
with a single symmetrically methylated three–fourth
HpaII site becomes evident, but not to the unmethylated
control cassette (Figure 3a and b). In other experiments
we found that binding is independent of Mg
++ ions in the
buﬀer (data not shown).
Next, we used complementary synthetic oligo-
nucleotides, annealed and M.SssI methylated in vitro,a s
described in ‘Materials and Methods’ section to further
deﬁne rMcrA-S’s binding preference. As Supplementary
Table 2b illustrates, these oligonucleotides all contain a
single CpG dinucleotide either preceded by D (A, G or
T) or followed by H (A, C or T). Figure 4 contains the
results of gel-shift assays with these methylated cassettes.
Under our standardized EMSA conditions, we found
that rMcrA-S preferentially shifts cassettes when a
Figure 3. Binding Assays for rMcrA-S. (A) Assays of electrophoretic mobility shifts with diﬀerent molar ratios (1:1 and 1:4—DNA:protein) of
rMcrA-S binding unmethylated and symmetrically methylated (m5CpG) containing 24-bp double-stranded oligonucleotides: 1 contains three m5C
including one in an HpaII site; 2 contains a single m5C in a ‘three–fourth HpaII site’; 3 contains a single m5C in an HpaII site; 4 has no m5Cs.
Molar ratios are based on monomeric McrA (16). Asterisks indicate the positions of McrA-S/DNA complexes. (B) Coomassie Blue staining of
EMSA (A) gel.
Figure 2. Bisulﬁte sequencing patterns of two genomic regions (C1 and C2) recovered after rMcrA-S aﬃnity-enrichment from MseI digested A549
DNA. Methylated cytosines in individual clones are depicted as ﬁlled symbols and unmethylated cytosines are open symbols. Individual circles
represent CpGs, double circles are the BstUI sites (CGCG), triangles are CGG sites, and rectangles are HpaII sites (CCGG).
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rather than a pyrimidine (Y) (m5CGY) (Figure 4a).
These ﬁndings suggest why our previous in vitro studies
revealed that McrA did not bind T7 DNA with
methylated HhaI sites (Gm5CGC) (16).
We also investigated the importance of cytosine preced-
ing m5CGR. Double-stranded cassettes were designed
with a single NCGR site, M.SssI methylated in vitro,
and then analyzed for rMcrA-S’s binding by EMSA.
rMcrA-S bound all eight cassettes (Figure 4b) but see-
mingly had a somewhat higher aﬃnity for duplexes with
Ym5CGR (Figure 4b, lanes 2, 4, 6 and 8) while shifting
duplex cassettes with a Rm5CGR sequence (Figure 4b,
lanes 1, 3, 5 and 7). These results are consistent with our
initial ﬁndings that rMcrA-S can aﬃnity-purify genomic
MseI fragments lacking a methylated HpaII site but con-
taining Am5CGG, a three–fourth HpaII site.
rMcrA-S also binds hemimethylated DNA
During mammalian DNA replication, CpG dinucleotides
in the daughter strand initially are unmethylated until
later methylated by the maintenance methyltransferase
(30). Therefore, we were interested to learn whether
rMcrA-S interacts with a hemimethylated Cm5CGG
sequence. For these studies, we annealed an oligonucleo-
tide with and without a single m5C added during synthesis
with its methylated- or non-methylated-complement
(Supplementary Table S3). As shown in Figure 5, the
added rMcrA-S gel shifts only the ds-cassettes with a
fully methylated or hemimethylated HpaII site and not
the unmethylated cassette. We next tested rMcrA-S’s
ability to gel-shift ds-cassettes wherein an A, C, T, U or
I residue is placed opposite the m5C (Figure 6).
Interestingly, EMSA shifts were observed only when a G
or I is opposite the m5C; no shifted complexes are seen
with the others.
DISCUSSION
From these experiments, we conclude that rMcrA-S can
bind ds-DNA fragments with a single symmetrically
methylated Cm5CGG sequence, or sites where Y
precedes, or R follows the methylated central CpG
dinucleotide. As shown here, electrophoresis of rMcrA-
S/DNA complexes on a polyacrylamide gel typically
generates two shifted bands. We believe these may repre-
sent mono-dimer equilibria of the complexes that form
during EMSA but additional studies will be needed to
adequately address this question. Interestingly, our
initial studies indicate that rMcrA-S does not demonstrate
high aﬃnity to human genomic CGIs with methylated
HpaII sites. Further work is needed with CGI-speciﬁc-
and other types of microarrays to determine if rMcrA-S
can be used for high-resolution DNA methylation analysis
of tiled CGIs and to verify if McrA is indeed a nuclease
in vivo. To date all our tests for double-stranded
DNA cleavage by McrA have been negative as have
assays for nicking activity on HpaII methylated
supercoiled plasmids and for m5C DNA glycosylase
activity. In addition, since we see no evidence for
Figure 4. rMcrA-S binds N(Y>R) m5CGR sequences. (A) EMSA showing rMcrA-S binding 24-bp oligonucleotide cassettes containing a purine
following the Cm5CG sequence (lanes 1, 2, 5 and 6) or with a pyrimidine following the Cm5CG (lanes 2, 3, 7 and 8). Lane 9 is a positive control
using a cassette with a single symmetrically methylated HpaII site; lanes 10 and 11 are negative controls. The molar ratio of HpaII sites to rMcrA-S
for each cassette is 1:4, or 1:6 (ratios based on monomeric rMcrA-S). (B) EMSA showing rMcrA-S binding 24-bp oligonucleotide cassettes con-
taining Nm5CGR sequences. rMcrA-S binds all cassettes with this sequence (lanes 1–8). Lane 9 contains an unmethylated cassette as a negative
control. The molar ratio of HpaII sites to rMcrA-S for each reaction is 1:6.
2002 Nucleic Acids Research, 2010,Vol.38, No. 6cleavage on long T7 DNA fragments with numerous sym-
metrically methylated HpaII sites, we do not believe that
McrA is similar to typeIIS restriction endonuclease
that cleave outside or between their recognition sites, as
is the case for McrBC.
Presumably, McrA acting simply as a DNA-binding
protein could interfere with or ‘biologically restrict’ the
maintenance or growth of m5C or Hm5C modiﬁed
plasmids and phages by interfering with DNA replication
(15) since, as shown here, it should bind in vivo to
Figure 5. EMSA showing rMcrA-S binding to DNA with fully- and hemi-methylated Cm5CGG sites. The molar ratio of HpaII sites to rMcrA-S
for each cassette is 1:4, 1:5, 1:6 and 1:7, increasing from left to right. Lanes 1–4 are fully methylated DNA, 5–8 are hemimethylated DNA, and lanes
9–12 are non-methylated DNA. Lanes 11 and 12 are negative controls. The band at the top of the gel is the sonicated non-methylated E. coli
competitor DNA.
Figure 6. rMcrA-S binding to DNA sequences with a mismatch opposite m5C. EMSA showing rMcrA-S binding to a DNA with a symmetrically
methylated HpaII site (lane 1), a hemi-methylated HpaII site (lane 2) and an inosine across from the m5C (lane 7). rMcrA-S does not bind if A, C, T
or U is opposite the m5C (lanes 3–6, respectively). The molar ratio of DNA to rMcrA-S is 1:6.
Nucleic Acids Research,2010, Vol.38, No. 6 2003symmetrically methylated as well as hemimethylated sites.
Alternatively, binding might not be tightly correlated with
cleavage speciﬁcity. McrA binding to m5C or Hm5C
modiﬁed sites might elicit post-translational modiﬁcation
of McrA, or alternatively the synthesis or interaction
with some other E. coli protein(s) needed to catalyze
cleavage in vivo. The recombinant McrA-S protein
described here should be useful in attempts to identify
such putative host protein(s) with which it might inter-
act in vivo to a form non-covalent, catalytically active
complex by co-chromatography on a Strep-Tactin
aﬃnity matrix (17).
Initial attempts to establish a pET-based McrA plasmid
in a Bl21(DE3) host harboring a pACYC-based clone of
the HpaII methylase that constitutively expresses
M.HpaII [kindly provided by Elisabeth Raleigh (NEB)]
were unsuccessful due to lethality caused by leaky expres-
sion of the McrA protein. Newer plasmid constructs in
which the expression of McrA-S sequence is more tightly
repressed (Studier, unpublished) have been introduced
into BL21-AI cells along with the M.HpaII plasmid. In
these cells the T7 RNA polymerase is under the control of
an arabinose promoter and has lower basal expression of
T7 RNA polymerase compared to BL21(DE3) cells (31).
These new constructs should be useful for understanding
the in vivo role of McrA in ‘restricting’ m5C- or
Hm5C-containing DNA.
Perhaps the most signiﬁcant ﬁnding of our present
study is the discovery that rMcrA-S can bind hemi-
methylated DNA and that a base mismatch, except for
I, opposite the m5C residues abrogates binding. Binding
of rMcrA-S to the m5C/I cassette is not totally
unanticipated since I opposite a m5C is expected to be
less destabilizing than A, C, T or U mismatches which is
consistent with the known base-pairing of dC:dI. These
results are in contrast to similar studies with (His)6-
tagged form of the methyl binding domain (MBD)
(residues 77–165) of the mouse MeCP2 protein (32,33).
It had been shown previously that the binding of the
MBD of MeCP2 requires only one methylated CpG
dinucleotide and that the MBD domain is necessary and
suﬃcient for binding of MeCP2 to its target duplex
(32,33). However, the MBD of MeCP2 binds equally
well to a 27 base long DNA cassette with a symmetrically
methylated CpG dinucleotide (m5C/m5C) as to one with a
T opposite the m5C (m5C/T) (34). The eﬀects of other
mismatches were not reported. The estimated Kd for a
hemimethylated CpG duplex is  10-fold higher than
that of a fully methylated CpG pair, whereas the Kd for
an unmethylated duplex is  100-fold higher. These data
are interpreted by Valinluck et al. (34) as being consistent
with MBD binding to its target duplex as a monomer that
recognizes both methylated cytosines in a fully methylated
duplex. McrA on the other hand appears to need only a
single m5CG in a Cm5CGG sequence for eﬃcient binding.
In this regard it is quite similar to the SRA (SET- and
RING ﬁnger-associated) domain of the mouse and
human UHRF1 proteins, which recent studies have
shown, binds selectively to DNAs with hemimethylated
CpG dinucleotides (35–38). These proteins increase their
protein–DNA interface by ﬂipping the m5C into a speciﬁc
protein binding pocket that stabilizes the complex. Similar
studies focusing on X-ray crystallization analysis of
McrA-S alone and when co-crystallized with methylated
and hemimethylated DNA cassettes will be needed to fully
understand the molecular basis of its interaction with
methylated DNA and whether it also utilizes a
base-ﬂipping mechanism to stabilize binding. It also will
be interesting to see if McrA can bind DNAs with Hm5C
residues and, if binding occurs, whether the diﬀerential
binding pattern is the same as for DNAs with m5C
residues. Preliminary data (JJD) indicate that McrA
binds but does not cleave T* DNA containing
non-glucosylated Hm5C residues.
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